EP Patent

EP3209336B1 — 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

Assigned to Deutsches Krebsforschungszentrum DKFZ · Expires 2019-12-11 · 6y expired

What this patent protects

Patent listed against Posluma.

Drugs covered by this patent

Patent Metadata

Patent number
EP3209336B1
Jurisdiction
EP
Classification
—
Expires
2019-12-11
Drug substance claim
No
Drug product claim
No
Assignee
Deutsches Krebsforschungszentrum DKFZ
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.